Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ozempic, Wegovy face US Medicare price negotiations
Former Trump health official: Medicare should cover Wegovy — but not negotiate its price
Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight-loss drugs — but says subjecting Wegovy to price controls is a bad move.
Medicare drug price negotiations to target Ozempic, Wegovy and other drugs
The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.
Marketplace
1d
Both Democrats and Republicans largely support funding Medicaid and Medicare, poll finds
Medicare and Medicaid are major sources of government spending, yet Democrats and Republicans alike support funding the ...
1d
on MSN
Biden administration picks 15 more drugs for Medicare negotiation
The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing ...
McKnight's Senior Living
1d
BREAKING NEWS: CMS announces updated Medicaid eligibility standards for 2025
The Centers for Medicare & Medicaid Services on Friday released an informational bulletin with updated federal poverty level ...
Modern Healthcare
2d
Medicare spending, insurance claim denials top concerns: KFF poll
Survey respondents pointed to federal health program spending, price transparency regulation and drug price negotiations as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback